20 April 2017

REDX PHARMA PLC: Appointment of Chairman 


Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that it has appointed Mr Iain Ross as Chairman of its Board of Directors and as a Non-Executive Director of the Company, effective from 1st May 2017.

Mr Ross has over 35 years’ of experience having held Senior Board and Management positions at multiple public and private companies in the life sciences sector.

Currently Mr Ross serves as Non-Executive Chairman of AIM quoted e-Therapeutics plc and Biomer Technology Ltd alongside his Non-Executive Directorships at London listed Premier Veterinary Group plc, and ASX quoted Anatara LifeSciences Ltd and Novogen Ltd and as a Director of Aldershot Town Football Club.

Iain’s previous executive positions include Executive Chairman at Silence Therapeutics plc (2005-2010), Chief Executive Officer at Allergy Therapeutics (2001-2002), Chief Executive Officer at Quadrant Healthcare plc (1995-2000) and Main Board Director of Celltech Group plc and CEO of Celltech Biologics (1991-1995). He has also been a Non-Executive Director at Benitec Biopharma (2010-2016), Phadia AB (2004-2007) and Eden BioDesign (2003-2007). Prior to this he worked at several multinational companies including Sandoz AG, Fisons plc and Hoffman La Roche.

Mr Ross is a qualified Chartered Director (UK IoD) and Vice Chairman of Royal Holloway, London University.

“Redx Pharma is a business of the highest quality that has discovered high value assets in cancer, immunology and infection and the opportunity to be part of progressing these promising assets through the clinic was instantly appealing. I look forward to working with the Board to realise the value of our best-in-class assets: RXC004 - Porcupine inhibitor and RXC005 - reversible BTK inhibitor, alongside several other promising assets in the Company’s pipeline.”

Iain Ross

Chairman of Redx Pharma

“I am delighted to welcome Iain Ross to Redx Pharma as Chairman of the Board. His extensive experience in the life science sector makes him the ideal candidate to take on this role. I am confident that under his stewardship the Company will deliver shareholder value as we transition into a clinical-stage research and development company with a focus on cancer, immunology and infection.”

Dr Neil Murray

Chief Executive Officer of Redx Pharma

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Iain Ross, aged 63 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current Directorships

  • Aldershot Town Football Club Ltd
  • Anatara LifeSciences Ltd
  • Biomer Technology Ltd
  • e-Therapeutics plc
  • Gladstone Consultancy Partnership
  • Gladstone Partners Ltd (Dormant)
  • Novogen Ltd
  • Pharminox Ltd
  • Premier Veterinary Group plc (formerly Ark Therapeutics Group plc)
  • Rosscard Leisure Ltd (Dormant)
  • Yellowcross Ltd

Previous Directorships 

  • Amarantus Bioscience Holdings Inc
  • Benitec Biopharma Ltd
  • Factor Therapeutics Europe Ltd
  • Powerstax Ltd
  • Redstoneconnect plc
  • Tacere Therapeutics Inc
  • Tissue Therapies Ltd
  • Tissue Therapies Europe Ltd
  • Trizell Ltd (formerly Ark Therapeutics Ltd)

Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information, please contact: 

Redx Pharma Plc
Neil Murray, Chief Executive Officer
T: +44 1625 469 900
Karl Hård, Head of Investor Relations &

Corporate Communications
T: +44 7491 651 406

Cantor Fitzgerald Europe (Nomad & Broker)
T: +44 20 7894 7000
Phil Davies/ Michael Reynolds

WG Partners LLP (Joint Broker)
T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson

Consilium Strategic Communications
Amber Fennell/ Matthew Neal/ Melissa Gardiner
T: +44 20 3709 5700

About Redx Pharma Plc

Company website: www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

Back to previous page